Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
← catalyst calendarNCT05697861 · readout ≤ 4,242 d
Sponsored by Intellia Therapeutics (industry) · NTLA — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
72estimated
Sites
4
Countries
France, New Zealand, Sweden +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-10 | actual | When the study began enrolling |
| Primary completion | Mar 2038 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2038 | estimated | The whole study's end, after follow-up |
| First posted | 2023-01-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
- Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy
- Wild-Type Transthyretin Cardiac Amyloidosis
Primary outcome
what the primary-completion date above is the date OFIncidence of Treatment-related SAEs and Protocol-specified AESIs
measured up to 15 years
Permalink · NTLA's whole pipeline · Catalyst calendar · Every registered study · What changed